The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers

Salivary gland cancers (SGC) are rare tumours with limited availability of systemic therapies. Some SGC subtypes overexpress HER2, and this represents a potential therapeutic target, but the evidence base is limited. This study sought to analyse real-world data on the efficacy of HER2-directed thera...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Joseph Edward Haigh, Karan Patel, Sam Rack, Pablo Jiménez-Labaig, Guy Betts, Kevin Joseph Harrington, Robert Metcalf
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2024-09-01
Edice:	Current Oncology
Témata:	salivary gland cancer HER2 trastuzumab TDM1 ado-trastuzumab emtansine trastuzumab deruxtecan
On-line přístup:	https://www.mdpi.com/1718-7729/31/9/419
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!